Drugs, Anti-Obesity Semaglutide at the Center of the New Cardio-Renal Protection

Il Tempo

newsbiella.it

View article

Sassuolo 2000

View article

+2 Reposted by 2 other sources

Right

Factuality

Ownership

ROME (ITALPRESS) - Heart and kidney protection is a priority in the management of people with type 2 diabetes, obesity and chronic kidney disease. A few days after the EASD Congress, the update presented in the framework of the European Society of Cardiology (ESC) recognizes semaglutide as one of the recommended therapies to reduce the risk of renal progression and cardiovascular events, confirming the contribution of Novo research in the cardio…

periodicodaily.com

Factuality

Ownership

(Adnkronos) - The update presented in the framework of the European Society of Cardiology (ESC) of the new EU guidelines The protection of heart and kidneys is a priority in the management of people with type 2 diabetes, obesity and chronic kidney disease. A few days from the Easd Congress, the update presented in the framework of the European Society of Cardiology (ESC) recognizes "semaglutide [...]

notizie.it

Rec News | Lontani dal mainstream

View article

canaledieci.it

View article

Calabria News

View article

Giornale Radio

View article

+4 Reposted by 4 other sources

Factuality

Ownership

(Adnkronos) - The update presented in the framework of the European Society of Cardiology (ESC) of the new EU guidelines The protection of the heart and kidneys is

italpress.com

Factuality

Ownership

ROME (ITALPRESS) - Heart and kidney protection is a priority in the management of people with type 2 diabetes, obesity and chronic kidney disease. A few days after the EASD Congress, the update presented in the framework of the European Society of Cardiology (ESC) recognizes semaglutide as one of the recommended therapies to reduce the risk of renal progression and [...]